结直肠癌数据集|医疗质量评估数据集

<p>国家结直肠癌审计（NBOCA）的目标是衡量在英格兰和威尔士的NHS医院中首次被诊断出患有结直肠癌的患者的护理质量和结果，以支持英国的结直肠单位提高患者所接受护理的质量。</p><p>数据特点：该数据集是英国官方发布的 “国家肠癌审计（National Bowel Cancer Audit, NBCA）2023 年度数据”，聚焦肠癌诊疗全流程的标准化审计与公共卫生监测，核心特点围绕 “临床真实数据 + 官方审计规范” 展开：</p><p><br></p><p><br></p><ul><li>数据来源与覆盖范围权威：数据由英国国家医疗服务体系（NHS）及相关医疗审计机构联合采集，覆盖英国境内接受肠癌诊疗的患者群体，包含公立医疗机构、私立合作机构的标准化诊疗记录，数据采集遵循《英国国家癌症审计框架》，确保样本的代表性与诊疗信息的规范性，无地域性偏差或数据遗漏。</li><li>信息维度聚焦诊疗全流程：核心数据围绕肠癌患者 “诊断 - 治疗 - 预后” 全链路设计，包含患者基础信息（年龄、性别、地域）、诊断信息（确诊方式如肠镜 / 影像学、癌症分期如 TNM 分期）、治疗方案（手术类型、化疗 / 放疗方案、靶向治疗使用情况）、诊疗质量指标（手术等待时间、术后并发症发生率）、短期预后数据（30 天 / 90 天生存率、再入院率）等，字段定义符合国际癌症诊疗数据标准，可直接用于跨机构、跨区域的诊疗质量对比。</li><li>数据隐私合规与去标识化：作为公共卫生审计数据，已对患者敏感信息（如姓名、身份证号、具体住址）进行匿名化处理，仅保留区域级地理信息（如郡 / 城市）和非识别性临床指标，符合欧盟《通用数据保护条例（GDPR）》及英国《数据保护法》，平衡数据可用性与隐私安全性。</li></ul><p>数据规模：为年度快照式数据集，2023 版为独立年度版本，可与 2022 年、2021 年等历史版本联动，形成 “时间序列诊疗趋势数据”，支撑长期诊疗质量变化分析。</p><p>应用场景：核心服务于公共卫生管理、医疗质量优化、医学研究三大领域，具体应用场景包括：</p><p><br></p><p><br></p><ul><li>公共卫生决策支持：英国卫生部门（如英格兰公共卫生署）可基于数据评估区域诊疗资源分配合理性（如某区域肠癌手术等待时间过长则需增加医疗资源）、制定癌症防控政策（如针对高发病率区域强化肠癌筛查宣传）；</li><li>医疗机构质量评估：作为肠癌诊疗机构的 “质量基准”，用于评估不同医院的诊疗合规性与效果（如对比不同医院的术后并发症发生率、生存率），推动医疗机构优化治疗流程、提升服务质量；</li><li>医学与流行病学研究：为临床研究人员提供真实世界研究（RWS）数据，用于分析肠癌诊疗方案的真实效果（如不同化疗方案在老年患者中的安全性差异）、探索影响预后的关键因素（如手术等待时间与生存率的关联），为肠癌诊疗指南更新提供数据支撑；</li><li>医疗政策与医保报销参考：辅助英国医保机构（如 NHS England）制定肠癌诊疗相关的医保报销政策，如基于不同治疗方案的成本 - 效果比，优化医保基金分配。</li></ul>

<p>The National Bowel Cancer Audit (NBOCA) aims to measure the quality of care and outcomes for patients newly diagnosed with colorectal cancer in NHS hospitals across England and Wales, to support colorectal units in the UK in improving the quality of care provided to patients.</p><p>Dataset Characteristics: This dataset is the 2023 annual data of the National Bowel Cancer Audit (NBCA), officially released by the UK, focusing on standardized audits and public health monitoring of the entire workflow of bowel cancer diagnosis and treatment. Its core features revolve around "real-world clinical data + official audit standards":</p><p><br></p><p><br></p><ul><li>Authoritative data sources and coverage: The data is jointly collected by the UK National Health Service (NHS) and relevant medical audit institutions, covering all patients receiving bowel cancer diagnosis and treatment in the UK, including standardized medical records from public medical institutions and private partner institutions. Data collection follows the UK National Cancer Audit Framework, ensuring the representativeness of the sample and the standardization of medical information, with no regional bias or data omission.</li><li>Focus on the entire diagnosis and treatment workflow in information dimensions: The core data is designed around the full workflow of "diagnosis - treatment - prognosis" for bowel cancer patients, including basic patient information (age, gender, region), diagnosis information (diagnosis methods such as colonoscopy/imaging, cancer staging such as TNM staging), treatment plans (surgical types, chemotherapy/radiotherapy regimens, targeted therapy usage), medical quality indicators (surgical waiting time, postoperative complication rate), short-term prognosis data (30-day/90-day survival rate, readmission rate), etc. The field definitions comply with international cancer diagnosis and treatment data standards, and can be directly used for cross-institutional and cross-regional comparison of medical quality.</li><li>Data privacy compliance and de-identification: As public health audit data, sensitive patient information (such as name, ID number, specific address) has been anonymized, only retaining regional-level geographic information (such as county/city) and non-identifiable clinical indicators, which complies with the EU General Data Protection Regulation (GDPR) and the UK Data Protection Act, balancing data availability and privacy security.</li></ul><p>Data Scale: It is an annual snapshot dataset. The 2023 version is an independent annual release, which can be linked with historical versions such as 2022 and 2021 to form "time-series diagnosis and treatment trend data", supporting long-term analysis of changes in medical quality.</p><p>Application Scenarios: It mainly serves three fields: public health management, medical quality optimization, and medical research. The specific application scenarios include:</p><p><br></p><p><br></p><ul><li>Public health decision support: UK health departments (such as Public Health England) can use this dataset to evaluate the rationality of regional medical resource allocation (for example, if the surgical waiting time for bowel cancer in a certain region is excessively long, medical resources need to be increased) and formulate cancer prevention and control policies (such as strengthening bowel cancer screening promotion in high-incidence regions);</li><li>Medical institution quality assessment: As a "quality benchmark" for bowel cancer diagnosis and treatment institutions, it is used to evaluate the medical compliance and effectiveness of different hospitals (such as comparing the postoperative complication rate and survival rate of different hospitals), promoting medical institutions to optimize treatment processes and improve service quality;</li><li>Medical and epidemiological research: Provide real-world study (RWS) data for clinical researchers, used to analyze the real-world effects of bowel cancer diagnosis and treatment plans (such as the safety differences of different chemotherapy regimens in elderly patients), explore key factors affecting prognosis (such as the correlation between surgical waiting time and survival rate), and provide data support for the update of bowel cancer diagnosis and treatment guidelines;</li><li>Medical policy and medical insurance reimbursement reference: Assist UK medical insurance institutions (such as NHS England) in formulating medical insurance reimbursement policies related to bowel cancer diagnosis and treatment, such as optimizing the allocation of medical insurance funds based on the cost-effectiveness ratio of different treatment plans.</li></ul>